Skip to content
DataLookout
Menu

NCT07816328

Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Minor Trial sites expanded: 1 → 5 locations
    • Primary and study completion dates: Jun 2, 2028 to May 24, 2028
  2. Notable Recruitment opened
    • Primary and study completion moved earlier from Jul 17, 2028 to Jun 2, 2028
    • Start date changed from estimate of Nov 9, 2026 to Sep 21, 2026
    • Study sites: 0 to 1
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of participants achieving Urticaria Activity Score over 7 days (UAS7) ≤6 (yes/no)
Timeframe: Week 24

Secondary (7)

Proportion of participants achieving UAS7 ≤6 (yes/no)
Proportion of participants achieving UAS7 =0 (yes/no)
Proportion of participants achieving Angioedema Activity Score over 7 days (AAS7) =0.
Proportion of participants achieving of Dermatology Life Quality Index (DLQI) =0/1
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Show 2 moreShow less
Proportion of participants achieving UAS7 ≤6 under the treatment algorithm compared with historical omalizumab (300 mg every 4 weeks) data.
Proportion of participants achieving UAS7 =0 under the treatment algorithm compared with historical omalizumab (300 mg every 4 weeks) data.

Arms and interventions

RemibrutinibExperimental

Participants will receive remibrutinib 25 mg twice a day for 12 weeks.

Remibrutinib or OmalizumabExperimental

Participants will receive remibrutinib 25 mg twice a day. At Week 12, well-controlled participants (UCT7 ≥12) continue remibrutinib, while participants with inadequate control (UCT7 \<12) escalate to omalizumab 300 mg every 4 weeks.

Drugs: Remibrutinib, Omalizumab

Sites

5 sites in 3 countries

Japan 3, Hong Kong 1, South Korea 1